Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study

被引：0
|
作者：
Yu, X. [1 ]
Shen, L. [2 ]
Hao, J. [3 ]
Wang, L. [4 ]
Pan, H. [5 ]
Han, G. [6 ]
Xu, J. [7 ]
Zhang, Y. [8 ]
Yang, S. [9 ]
Ying, J. [10 ]
Li, M. [11 ]
Begic, D. [12 ]
Lu, B. [12 ]
Xu, R. [13 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai 200433, Peoples R China
[2] Peking Univ, Canc Hosp, Beijing Canc Hosp, Oncol, Beijing 100871, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Oncol, Tianjin, Peoples R China
[4] 1st Shanghai Peoples Hosp, Oncol, Shanghai, Peoples R China
[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Oncol, Hangzhou 310003, Zhejiang, Peoples R China
[6] 4th Mil Med Univ, Xijing Hosp, Oncol, Xian, Peoples R China
[7] 307th Hosp PLA AMMS China, Oncol, Beijing, Peoples R China
[8] 1st Hosp Harbin Inst Hematol, Oncol, Harbin, Peoples R China
[9] Henan Prov Anticanc Hosp, Oncol, Zhengzhou, Peoples R China
[10] Zhejiang Canc Hosp, Oncol, Hangzhou, Zhejiang, Peoples R China
[11] Celgene, Biostat, Summit, NJ USA
[12] Celgene, CR&D, Summit, NJ USA
[13] Sun Yat Sen Univ, Affiliated Hosp 1, Oncol, Guangzhou 510275, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
223P
引用
收藏
页码：66 / 67
页数：2
相关论文
共 50 条
  • [21] A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)
    De Jesus-Acosta, Ana
    O'Dwyer, Peter J.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Maitra, Anirban
    Rasheed, Zeshaan
    Zheng, Lei
    Rajeshkumar, N. V.
    Le, Dung T.
    Hoering, Antje
    Bolejack, Vanessa
    Yabuuchi, Shinichi
    Laheru, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [22] A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) plus apatorsen (A) or placebo (PI) in patients (pts) with metastatic pancreatic cancer (mPC): The RAINIER trial
    Ko, Andrew H.
    Murphy, Patrick Brian
    Peyton, James D.
    Shipley, Dianna
    Al-Hazzouri, Ahmed
    Rodriguez, Francisco Antonio
    Womack, Mark Sanders
    Xiong, Henry Q.
    Waterhouse, David Michael
    Tempero, Margaret A.
    Guo, Shuangli
    Lane, Cassie Michelle
    Earwood, Christopher
    DeBusk, Laura M.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study
    Von Hoff, D. D.
    Ramanathan, R.
    Borad, M.
    Laheru, D.
    Smith, L.
    Wood, T.
    Korn, R.
    Desai, N.
    Iglesias, J.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).
    Philip, Philip Agop
    Lacy, Jill
    Dowden, Scot D.
    Sastre, Javier
    Bathini, Venu Gopal
    Cardin, Dana Backlund
    Ma, Wen Wee
    Sobrero, Alberto F.
    Koski, Sheryl L.
    Borg, Christophe
    Tonini, Giuseppe
    Rivera, Fernando
    Hwang, Jimmy J.
    Knoble, Jeanna L.
    Al Baghdadi, Tareq
    Saif, Wasif M.
    Meiri, Eyal
    Kayitalire, Louis
    Li, Jack
    Hammel, Pascal
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [25] APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)
    Tempero, M. A.
    Cardin, D.
    Biankin, A.
    Goldstein, D.
    Moore, M.
    O'Reilly, E. M.
    Philip, P.
    Riess, H.
    Macarulla, T.
    Yung, L.
    Wei, X.
    Lu, B.
    PANCREAS, 2014, 43 (08) : 1416 - 1416
  • [26] RAINIER: A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) combined with apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC).
    Ko, Andrew H.
    Murphy, Patrick B.
    Peyton, James D.
    Shipley, Dianna
    Al-Hazzouri, Ahmed
    Rodriguez, Frank A.
    Womack, Mark S.
    Xiong, Henry Q.
    Waterhouse, David M.
    Tempero, Margaret A.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [27] Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).
    Moore, Malcolm J.
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Hon, Jeremy K.
    Biakhov, Mikhail Yu
    Hingorani, Sunil R.
    Ganju, Vinod
    Weekes, Colin D.
    Scheithauer, Werner
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Goldstein, David
    Wei, Xinyu
    Romano, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Efficacy and cost of nab-paclitaxel (nab-P) in metastatic melanoma (mM)
    Agarwala, Sanjiv S.
    Whiting, Scott
    Binder, Gary
    Hersh, Evan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Phase 1 study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo plus nab-P in arm A
    Hochster, Howard S.
    Wainberg, Zev A.
    Gutierrez, Martin
    Waterhouse, David
    Chiorean, E. Gabriela
    George, Ben
    Ko, Amy
    Manax, Victoria
    Stergiopoulos, Sotirios
    O'Dwyer, Peter
    CANCER RESEARCH, 2016, 76
  • [30] Efficacy and safety of nab-paclitaxel (nab-P) in patients (pts) with previously treated metastatic colorectal cancer (mCRC): The phase II COLO-001 trial
    Ducreux, M.
    Bennouna, J.
    Adenis, A.
    Conroy, T.
    Lievre, A.
    Portales, F.
    McGovern, D.
    Li, L.
    Romano, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S376 - S376
12345